GlobeNewswire

Cisco Tetration Workload Protection Extended with New Options: SaaS and Virtual Appliance

Dela

New Tetration models deliver faster deployment and pay-as-you-grow flexibility

 

SAN JOSE, Calif., April 10, 2018 (GLOBE NEWSWIRE) -- Cisco today announced two new consumption models for its Cisco® Tetration solution for the data center and cloud: Tetration SaaS, the cloud-based solution for cloud-first and cloud-only organizations, and Tetration-V, a software-only version using a virtual appliance for smaller deployments. Both models deliver the same features and functionality as the original on-premises form factors of Tetration. Tetration automates application dependency mapping and whitelist policy generation and enforcement, gives insight into network performance, and offers cloud workload protection. The Tetration  APIs enable IT organizations to create custom applications with access to Tetration data sources, allowing the export and enforcement of policies generated by Tetration across SDN controllers and security devices.

With the new consumption models, organizations can adopt Tetration technology within hours, with no initial investment and the flexibility to pay as they grow.

With Tetration SaaS, organizations gain the benefits of a fully managed model, including:

  • Workload protection features without any on-premises hardware requirements
  • Protection for on-premises, public, and private cloud workloads
  • Scalability up to 25,000 workloads
  • Data retention for months
  • Faster onboarding to realize the benefits of the platform quickly
  • Built-in high availability and disaster recovery capability
  • Service backed by world-class SLAs
  • Managed services provided by Cisco channel partners

For organizations that deploy fewer than 1000 workloads and prefer a software-only approach, Tetration is available on a virtual appliance. It offers one-click deployment and allows organizations to use their own server and storage infrastructure. 

Both Tetration models deliver a ready-to-use solution to identify data center applications, their detailed dependencies, and the underlying policies between different application tiers. Operators can implement a zero-trust model using whitelist policy and segmentation, monitor the behavior of server processes, and identify software-related vulnerabilities. Tetration is able to identify high-severity security events such as certain Spectre and Meltdown exploits using behavior-based anomalies, allowing proactive quarantining of affected servers. With this approach, Tetration provides holistic cloud workload protection anywhere. For more information, see A Recipe to Keep Your Hybrid Cloud Workloads Safe.

"Cisco Tetration helps Xentaurs manage successful cloud and data center deployments for our clients by ensuring every single connection and flow to an application is visible," said Anoj Willy, CEO, Xentaurs. "Without this critical information, app, cloud, and data center migrations would be impossible to precisely guarantee nothing is missed and everything is as it is intended. Tetration goes further in establishing and enforcing a zero-trust environment that is the foundation for microsegmentation, down to containers and next-generation services development."

Cisco's architectural approach to security 
Tetration is also a core technology in Cisco's data center security and workload protection portfolio. Tetration works with Cisco ACI and Cisco's security portfolio, including Cisco Firepower® Next-Generation Firewall (NGFW), Next-Generation IPS (NGIPS), Advanced Malware Protection (AMP), and Stealthwatch® to deliver effective security that follows the workload everywhere. Now operators can see everything across their network, reduce the attack surface, and stop data center breaches from moving laterally across workloads.  For more information, see Redefining Security for the Modern Data Center in a Multi-Cloud World.

Cisco Services for Tetration
If requested, Cisco can also provide professional and support services for Tetration SaaS and Tetration-V, including: support for Tetration onboarding and use-case support to accelerate Tetration adoption and optimize policies and security, resulting in a faster time to value with Tetration.  

Availability
Cisco Tetration SaaS is scheduled to be available in May 2018. Tetration-V is available now. 

Additional resources   
Learn more about Cisco TetrationLearn more about Cisco ACI(TM)
Learn more about Cisco ACI ecosystem partnersLearn more about Cisco data center technologyLearn more about Services for Cisco Tetration

About Cisco
Cisco (NASDAQ:CSCO) is the worldwide technology leader that has been making the Internet work since 1984. Our people, products, and partners help society securely connect and seize tomorrow's digital opportunity today. Discover more at thenetwork.cisco.com and follow us on Twitter at @Cisco.

Cisco and the Cisco logo are trademarks or registered trademarks of Cisco and/or its affiliates in the U.S. and other countries. A listing of Cisco's trademarks can be found at www.cisco.com/go/trademarks. Third-party trademarks mentioned are the property of their respective owners. The use of the word partner does not imply a partnership relationship between Cisco and any other company.

RSS Feed for Cisco: http://newsroom.cisco.com/rss-feeds

Press Relations: 
Lee Davis   
Cisco 
650-868-3036
leedavis@cisco.com             
Analyst Relations:
Aimee Schoaf 
Cisco 
623-377-0377
aschoaf@cisco.com             
Investor Relations:
Carol Villazon
Cisco
408-527-6538
carolv@cisco.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Cisco via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Immunicum AB (publ) Announces Upcoming Investor Events in January22.1.2019 08:30Pressmeddelande

Press Release 22 January 2019 Immunicum AB (publ) Announces Upcoming Investor Events in January Immunicum AB (publ; IMMU.ST) announced today that Carlos de Sousa, CEO of Immunicum, and other members of the management team will present at upcoming investor conferences in January. Biomed Investor Event by Invest Securities Date: January 22, 2019 Venue: Les Salons Hoche, 9 Avenue Hoche, Paris, France Redeye Fight Cancer Seminar Date: January 22, 2019 Presentation Time: 11.15 am CET Panel: 11.25 am CET Venue: Master Samuelsgatan 42, Stockholm, Sweden Aktiespararna - Stora Aktiedagen Date: January 29, 2019 Presentation Time: 8.30 - 9.00 am CET Panel: "Samtal om cancerbekämpning", 10:50 am CET Venue: Medicon Village, Scheelevägen 2, Lund, Sweden For more information, please contact: Carlos de Sousa, CEO, Immunicum Telephone: +46 (0) 31 41 50 52 E-mail: info@immunicum.com Michaela Gertz, CFO, Immunicum Telephone: +46 70 926 17 75 E-mail: ir@immunicum.com Media Relations Gretchen Schweitzer an

Immunicum AB (publ) meddelar idag kommande presentationstillfällen under januari22.1.2019 08:30Pressmeddelande

Pressmeddelande 22 januari 2019 Immunicum AB (publ) meddelar idag kommande presentationstillfällen under januari Immunicum AB (publ; IMMU.ST) meddelar idag att Immunicums VD, Carlos de Sousa och andra medlemmar av ledningsgruppen kommer presentera vid följande investerarevent under januari. Biomed Investor Event by Invest Securities Datum: 22 januari 2019 Plats: Les Salons Hoche, 9 Avenue Hoche, Paris, France RedEye Fight Cancer Seminar Datum: 22 januari 2019 Presentationstid: 11.15 am CET Panel: 11.25 am CET Plats: Master Samuelsgatan 42, Stockholm, Sweden Aktiespararna - Stora Aktiedagen Datum: 29 januari 2019 Presentationstid: 8.30 - 9.00 am CET Panel: "Samtal om cancerbekämpning", 10:50 am CET Plats: Medicon Village, Scheelevägen 2, Lund, Sweden För ytterligare information kontakta: Carlos de Sousa, VD, Immunicum Telefon: +46 (0) 31 41 50 52 E-post: info@immunicum.com Michaela Gertz, Finanschef, Immunicum Telefon: +46 (0) 70 926 17 75 E-post: ir@immunicum.com Media Relations Gretch

Immunicum AB (publ) meddelar att resultaten från den kliniska fas I/II-studien med ilixadencel vid långt framskriden levercancer publicerats i Frontiers in Oncology21.1.2019 08:30Pressmeddelande

Pressmeddelande 21 januari 2019 Immunicum AB (publ) meddelar att resultaten från den kliniska fas I/II-studien med ilixadencel vid långt framskriden levercancer publicerats i Frontiers in Oncology Immunicum AB (publ; IMMU.ST) meddelar idag att den slutliga analysen av data från den undersökande kliniska studien med ilixadencel hos patienter med långt framskriden levercancer har publicerats i tidskriften, Frontiers in Oncology . Dessa data bekräftar de tidigare meddelade positiva egenskaperna gällande säkerhet och tolerabilitet för ilixadencel, både när det ges som enda behandling och i kombination med första linjens standardbehandling, sorafenib. Dessutom påvisades ökade nivåer av tumörspecifika CD8+ T-celler i cirkulerande blod för en majoritet av de utvärderbara patienterna, vilket indikerar ett systemiskt immunologiskt svar. De fullständiga resultaten ger ytterligare insikter om ilixadencels verkningsmekanism, tecken på klinisk effekt samt viktig information som kommer att vara vägl

Immunicum AB (publ) Announces Publication of Phase I/II Clinical Trial Results of Ilixadencel in Advanced Hepatocellular Carcinoma in Frontiers in Oncology21.1.2019 08:30Pressmeddelande

Press Release 21 January 2019 Immunicum AB (publ) Announces Publication of Phase I/II Clinical Trial Results of Ilixadencel in Advanced Hepatocellular Carcinoma in Frontiers in Oncology Immunicum AB (publ; IMMU.ST) announced today that the final data analysis from the exploratory clinical study of ilixadencel in patients with advanced hepatocellular carcinoma (HCC) has been published in the journal, Frontiers in Oncology . The data confirms previously communicated positive safety and tolerability of ilixadencel when administered both alone and in combination with current first-line standard of care, sorafenib. In addition, the data demonstrate an increased frequency of tumor-specific CD8+ T cells in circulating blood for a majority of evaluable patients, indicating a systemic immune response. The complete results provide further insight on ilixadencel's mode of action, signs of clinical activity and important information that will guide the next stage of clinical development. As commun

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum